Mutations in ARID1A are frequent in non-small cell lung cancer, colon cancer, bladder cancer and breast cancer, whereas mutations in KEAP1 and STK11 was predominate in non-small cell lung cancer (8.62% and 11.75%, respectively) (Fig. 5B). Here, ARID1A is linked to breast cancer.